CA2602247C — Piperazine-substituted benzothiophenes for treatment of mental disorders
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2013-04-02 · 13y expired
What this patent protects
The present invention provides a heterocyclic compound represented by the general formula (1): (see formula 1) The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
USPTO Abstract
The present invention provides a heterocyclic compound represented by the general formula (1): (see formula 1) The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.